Answers are grounded in this paper and cite their sources.
Evaluation of tri-color fluorescence FISH improves detection and diagnosis of BCR/ABL1 fusion in chronic myeloid leukemia patients.
BACKGROUND: Chronic myelogenous leukemia (CML) is characterized by the t(9;22)(q34;q11.2), which forms the BCR/ABL1 fusion gene. The t(9;22) may be linked to cryptic submicroscopic deletions on chromosomes 9 and/or 22, which maybe associated with unfavorable behavior. Fluorescence in situ hybridization (FISH) analysis is used to determine the number of interphase cells exhibiting BCR/ABL1 fusion with its typical dual-fusion pattern and also can detect cryptic deletions in the form of atypical signal patterns. Serial FISH testing is valuable for follow-up and monitoring therapy response. AIMS AND OBJECTIVES: This work evaluated the implementation of the BCR-ABL1 + 9q34 tri-color plus dual-fusion FISH (D-FISH) system in identifying fusion signal patterns, in comparison with dual-color D-FISH, and to explore its value in detecting BCR/ABL1 fusion and ASS1 gene deletion. MATERIALS AND METHODS: A total of 104 samples from CML patients were analyzed using commercially available BCR-ABL1 dual-color D-FISH and tri-color dual-fusion probes, and their signal profiles were compared. RESULTS: While D-FISH was effective for identifying typical fusion signals, the tri-color probe improved interpretation by distinguishing true fusions from overlapping signals through its aqua-labeled ASS1 component and additionally enabled direct recognition of ASS1 deletions. CONCLUSION: The tri-color dual-fusion probe allows broader detection of molecular variants, reliably distinguishing cryptic deletions from signal overlaps, reduces false positives, and enables direct ASS1 deletion detection, improving BCR/ABL1 fusion diagnosis and measurable residual disease monitoring.
No takes yet. Share an insight, caveat, or question.
Imbaby et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: